Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib, Capecitabine, and Ado-Trastuzumab Emtansine in HER2-Positive Breast Cancer With Brain Metastases
NCT01494662Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2012
- Primary completion
- Feb 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in breast cancer, brain metastases, sponsored by Dana-Farber Cancer Institute. Started Feb 2012; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on NCT01494662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01494662.